REFERENCES
1. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65:1-11.
2. Martins-Martinho J, Dourado E, Khmelinskii N, Espinosa P, Ponte C. Localized forms of vasculitis. Curr Rheumatol Rep. 2021;23:49.
3. Hernández-Rodríguez J, Molloy ES, Hoffman GS. Single-organ vasculitis. Curr Opin Rheumatol. 2008;20:40-6.
4. Hernández-Rodríguez J, Hoffman GS. Updating single-organ vasculitis. Curr Opin Rheumatol. 2012;24:38-45.
5. Salvarani C, Calamia KT, Crowson CS, et al. Localized vasculitis of the gastrointestinal tract: a case series. Rheumatology. 2010;49:1326-35.
6. Burke AP, Sobin LH, Virmani R. Localized vasculitis of the gastrointestinal tract. Am J Surg Pathol. 1995;19:338-49.
7. Hernández-Rodríguez J, Tan CD, Rodríguez ER, Hoffman GS. Single-organ gallbladder vasculitis: characterization and distinction from systemic vasculitis involving the gallbladder. An analysis of 61 patients. Medicine. 2014;93:405-13.
8. Gayraud M, Guillevin L, Le Toumelin P, et al. the French Vasculitis Study Group. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheumatism. 2001;44:666-75.
9. Hilhorst M, van Paassen P, Tervaert JW. Limburg Renal Registry. Proteinase 3-ANCA vasculitis versus myeloperoxidase-ANCA vasculitis. J Am Soc Nephrol. 2015;26:2314-27.
10. Watts RA, Mahr A, Mohammad AJ, Gatenby P, Basu N, Flores-Suárez LF. Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Nephrol Dial Transplant. 2015;30 Suppl 1:i14-22.
11. Unizony S, Villarreal M, Miloslavsky EM, et al. RAVE-ITN Research Group. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis. 2016;75:1166-9.
12. Cabral DA, Canter DL, Muscal E, et al. ARChiVe Investigators Network within the PedVas Initiative. Comparing presenting clinical features in 48 children with microscopic polyangiitis to 183 children who have granulomatosis with polyangiitis (Wegener’s): an ARChiVe cohort study. Arthritis Rheumatol. 2016;68:2514-26.
13. Jóźwiak L, Ławnicka I, Książek A. Coexistence of granulomatosis with polyangiitis (GPA) and Crohn’s disease or multiorgan manifestation of the same disease? Reumatologia. 2016;54:86-90.
14. Jayne DRW, Merkel PA, Schall TJ, Bekker P. ADVOCATE Study Group. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384:599-609.
15. Walsh M, Merkel PA, Peh CA, et al. PEXIVAS Investigators. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020;382:622-31.
16. Karadag O, Jayne DJ. Polyarteritis nodosa revisited: a review of historical approaches, subphenotypes and a research agenda. Clin Exp Rheumatol. 2018;36 Suppl 111:135-42.
17. Lightfoot RW Jr, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum. 1990;33:1088-93.
18. Guillevin L, Lhote F, Cohen P, et al. Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine. 1995;74:238-53.
19. Stanson AW, Friese JL, Johnson CM, et al. Polyarteritis nodosa: spectrum of angiographic findings. Radiographics. 2001;21:151-9.
21. Levine SM, Hellmann DB, Stone JH. Gastrointestinal involvement in polyarteritis nodosa (1986-2000): presentation and outcomes in 24 patients. Am J Med. 2002;112:386-91.
22. Fortin PR, Larson MG, Watters AK, Yeadon CA, Choquette D, Esdaile JM. Prognostic factors in systemic necrotizing vasculitis of the polyarteritis nodosa group - a review of 45 cases. J Rheumatol. 1995;22:78-84.
23. Pagnoux C, Seror R, Henegar C, et al. French Vasculitis Study Group. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French vasculitis study group database. Arthritis Rheum. 2010;62:616-26.
24. Pagnoux C, Mahr A, Cohen P, Guillevin L. Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides: analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated vasculitis. Medicine. 2005;84:115-28.
25. Becker A, Mader R, Elias M, Lev A, Sayfan J. Duodenal necrosis as the presenting manifestation of polyarteritis nodosa. Clin Rheumatol. 2002;21:314-6.
26. Carpi JM, Castejón E, Masiques L, Vilar P, Antón J, Varea V. Gastrointestinal involvement in pediatric polyarteritis nodosa. J Pediatr Gastroenterol Nutr. 2007;44:274-8.
27. Kariv R, Sidi Y, Gur H. Systemic vasculitis presenting as a tumorlike lesion. Four case reports and an analysis of 79 reported cases. Medicine. 2000;79:349-59.
28. NUZUM JW Jr. Polyarteritis nodosa; statistical review of one hundred seventy-five cases from the literature and report of a typical case. AMA Arch Intern Med. 1954;94:942-55.
29. Thorne JC, Bookman AA, Stevens H. A case of polyarteritis presenting as abrupt onset of pancreatic insufficiency. J Rheumatol. 1980;7:583-6.
30. Iuliano L, Gurgo A, Gualdi G, Bonavita MS. Succeeding onset of hepatic, splenic, and renal infarction in polyarteritis nodosa. Am J Gastroenterol. 2000;95:1837-8.
31. Empen K, Jung MC, Engelhardt D, Sackmann M. Successful treatment of acute liver failure due to polyarteritis nodosa. Am J Med. 2002;113:349-51.
32. Goritsas CP, Repanti M, Papadaki E, Lazarou N, Andonopoulos AP. Intrahepatic bile duct injury and nodular regenerative hyperplasia of the liver in a patient with polyarteritis nodosa. J Hepatol. 1997;26:727-30.
33. Fernandes SR, Samara AM, Magalhães EP, Sachetto Z, Metze K. Acute cholecystitis at initial presentation of polyarteritis nodosa. Clin Rheumatol. 2005;24:625-7.
34. Frohnert PP, Sheps SG. Long-term follow-up study of periarteritis nodosa. Am J Med. 1967;43:8-14.
35. Guillevin L, Le Thi Huong Du, Godeau P, Jais P, Wechsler B. Clinical findings and prognosis of polyarteritis nodosa and Churg-Strauss angiitis: a study in 165 patients. Br J Rheumatol. 1988;27:258-64.
36. Guillevin L, Cohen P, Mahr A, et al. Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. Arthritis Rheum. 2003;49:93-100.
37. Zhou Q, Yang D, Ombrello AK, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med. 2014;370:911-20.
38. Navon Elkan P, Pierce SB, Segel R, et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med. 2014;370:921-31.
39. Jee H, Huang Z, Baxter S, et al. Comprehensive analysis of ADA2 genetic variants and estimation of carrier frequency driven by a function-based approach. J Allergy Clin Immunol. 2022;149:379-87.
40. Huang Z, Li T, Nigrovic PA, Lee PY. Polyarteritis nodosa and deficiency of adenosine deaminase 2 - Shared genealogy, generations apart. Clin Immunol. 2020;215:108411.
41. Lee PY, Kellner ES, Huang Y, et al. Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2). J Allergy Clin Immunol. 2020;145:1664-72.e10.
42. Lee PY. Vasculopathy, immunodeficiency, and bone marrow failure: the intriguing syndrome caused by deficiency of adenosine deaminase 2. Front Pediatr. 2018;6:282.
43. Meyts I, Aksentijevich I. Deficiency of adenosine deaminase 2 (DADA2): updates on the phenotype, genetics, pathogenesis, and treatment. J Clin Immunol. 2018;38:569-78.
44. Caorsi R, Penco F, Grossi A, et al. ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study. Ann Rheum Dis. 2017;76:1648-56.
45. Ombrello AK, Qin J, Hoffmann PM, et al. Treatment strategies for deficiency of adenosine deaminase 2. N Engl J Med. 2019;380:1582-4.
46. Liang P, Hoffman GS. Advances in the medical and surgical treatment of Takayasu arteritis. Curr Opin Rheumatol. 2005;17:16-24.
48. Numano F. Vasa vasoritis, vasculitis and atherosclerosis. Int J Cardiol. 2000;75 Suppl 1:S1-8; discussion S17.
49. Moriwaki R, Numano F. Takayasu arteritis: follow-up studies for 20 years. Heart Vessels Suppl. 1992;7:138-45.
50. Goel R, Gribbons KB, Carette S, et al. Derivation of an angiographically based classification system in Takayasu’s arteritis: an observational study from India and North America. Rheumatology. 2020;59:1118-27.
51. Schmidt J, Kermani TA, Bacani AK, et al. Diagnostic features, treatment, and outcomes of Takayasu arteritis in a US cohort of 126 patients. Mayo Clin Proc. 2013;88:822-30.
52. Terao C, Matsumura T, Yoshifuji H, et al. Takayasu arteritis and ulcerative colitis: high rate of co-occurrence and genetic overlap. Arthritis Rheumatol. 2015;67:2226-32.
53. Sy A, Khalidi N, Dehghan N, et al. Vasculitis Clinical Research Consortium (VCRC); Canadian Vasculitis Network (CanVasc). Vasculitis in patients with inflammatory bowel diseases: a study of 32 patients and systematic review of the literature. Semin Arthritis Rheum. 2016;45:475-82.
54. Laurent C, Ricard L, Fain O, et al. PET/MRI in large-vessel vasculitis: clinical value for diagnosis and assessment of disease activity. Sci Rep. 2019;9:12388.
55. Jia S, Liu L, Ma J, Chen X. Application progress of multiple imaging modalities in Takayasu arteritis. Int J Cardiovasc Imaging. 2021;37:3591-601.
56. Saadoun D, Lambert M, Mirault T, et al. Retrospective analysis of surgery versus endovascular intervention in Takayasu arteritis: a multicenter experience. Circulation. 2012;125:813-9.
57. Alibaz-Oner F, Kaymaz-Tahra S, Bayındır Ö, et al. Biologic treatments in Takayasu’s arteritis: a comparative study of tumor necrosis factor inhibitors and tocilizumab. Semin Arthritis Rheum. 2021;51:1224-9.
58. Mason JC. Takayasu arteritis - advances in diagnosis and management. Nat Rev Rheumatol. 2010;6:406-15.
59. Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. Polymyalgia rheumatica and giant cell arteritis: a systematic review. JAMA. 2016;315:2442-58.
61. Evans JM, O’Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med. 1995;122:502-7.
62. Bienvenu B, Ly KH, Lambert M, et al. Groupe d’Étude Français des Artérites des gros Vaisseaux; under the Aegis of the Filière des Maladies Auto-Immunes et Auto-Inflammatoires Rares. Management of giant cell arteritis: recommendations of the French study group for large vessel vasculitis (GEFA). Rev Med Interne. 2016;37:154-65.
63. Sangha S, Lenert A, Dawoud S, et al. Atypical large vessel vasculitis presenting with cholestatic liver abnormalities: case-based review. J Clin Rheumatol. 2021;27:e561-7.
64. Scola CJ, Li C, Upchurch KS. Mesenteric involvement in giant cell arteritis. An underrecognized complication? Medicine. 2008;87:45-51.
65. Lee S, Childerhouse A, Moss K. Gastrointestinal symptoms and granulomatous vasculitis involving the liver in giant cell arteritis: a case report and review of the literature. Rheumatology. 2011;50:2316-7.
66. Heneghan MA, Feeley KM, DeFaoite N, Little MP, O’Gorman TA. Granulomatous liver disease and giant-cell arteritis. Dig Dis Sci. 1998;43:2164-7.
67. Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377:317-28.
68. Piram M, Mahr A. Epidemiology of immunoglobulin A vasculitis (Henoch-Schönlein): current state of knowledge. Curr Opin Rheumatol. 2013;25:171-8.
69. Audemard-Verger A, Pillebout E, Baldolli A, et al. Impact of aging on phenotype and prognosis in IgA vasculitis. Rheumatology. 2021;60:4245-51.
70. Ebert EC. Gastrointestinal manifestations of Henoch-Schonlein Purpura. Dig Dis Sci. 2008;53:2011-9.
71. Gendreau S, Porcher R, Thoreau B, et al. French Vasculitis Study Group. Characteristics and risk factors for poor outcome in patients with systemic vasculitis involving the gastrointestinal tract. Semin Arthritis Rheum. 2021;51:436-41.
72. Nossent J, Raymond W, Isobel Keen H, Preen D, Inderjeeth C. Morbidity and mortality in adult-onset IgA vasculitis: a long-term population-based cohort study. Rheumatology. 2021;61:291-8.
73. Bailey M, Chapin W, Licht H, Reynolds JC. The effects of vasculitis on the gastrointestinal tract and liver. Gastroenterol Clin North Am. 1998;27:747-82.
74. Audemard-Verger A, Pillebout E, Guillevin L, Thervet E, Terrier B. IgA vasculitis (Henoch-Shönlein purpura) in adults: diagnostic and therapeutic aspects. Autoimmun Rev. 2015;14:579-85.
75. Pillebout E, Verine J. [Henoch-Schönlein purpura in the adult]. Rev Med Interne. 2014;35:372-81.
76. Pillebout E, Rocha F, Fardet L, Rybojad M, Verine J, Glotz D. Successful outcome using rituximab as the only immunomodulation in Henoch-Schonlein purpura: case report. Nephrol Dial Transplant. 2011;26:2044-6.
77. Chou T, Louissant VR, Adams A, et al. Successful treatment of Henoch-Schönlein purpura with recurrent gastrointestinal involvement with mycophenolate mofetil: a brief report. Clin Pediatr. 2015;54:900-3.
79. Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med. 1974;57:775-88.
80. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 1992;327:1490-5.
81. Retamozo S, Díaz-Lagares C, Bosch X, et al. Life-threatening cryoglobulinemic patients with hepatitis C: clinical description and outcome of 279 patients. Medicine. 2013;92:273-84.
82. Dammacco F, Racanelli V, Russi S, Sansonno D. The expanding spectrum of HCV-related cryoglobulinemic vasculitis: a narrative review. Clin Exp Med. 2016;16:233-42.
83. Ferri C, Sebastiani M, Giuggioli D, et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum. 2004;33:355-74.
84. De Vita S, Soldano F, Isola M, et al. Preliminary classification criteria for the cryoglobulinaemic vasculitis. Ann Rheum Dis. 2011;70:1183-90.
85. Mukhtyar C, Guillevin L, Cid MC, et al. European Vasculitis Study Group. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68:310-7.
86. Saadoun D, Resche Rigon M, Sene D, et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood. 2010;116:326-34.
87. Oykhman P, Hamilton MA, Aaron SL. Multiorgan failure from cryoglobulinemic vasculitis following intravenous immunoglobulin replacement therapy. J Clin Rheumatol. 2016;22:441-3.
88. Chen J, Yao X. A contemporary review of Behcet’s syndrome. Clin Rev Allergy Immunol. 2021;61:363-76.
89. Meo N, Bergamo S, Vidimari P, Bonin S, Trevisan G. Analysis of diagnostic criteria in adamantiades-behçet disease: a retrospective study. Indian J Dermatol. 2013;58:275-7.
91. Lee SK, Kim BK, Kim TI, Kim WH. Differential diagnosis of intestinal Behçet’s disease and Crohn’s disease by colonoscopic findings. Endoscopy. 2009;41:9-16.
92. Lee CR, Kim WH, Cho YS, et al. Colonoscopic findings in intestinal Behçet’s disease. Inflamm Bowel Dis. 2001;7:243-9.
93. Grigg EL, Kane S, Katz S. Mimicry and deception in inflammatory bowel disease and intestinal behçet disease. Gastroen Hepatol. 2012;8:103-12.
94. Yanai S, Matsumoto T. Biologic drugs for inflammatory bowel disease. Nihon Rinsho. 2017;75:403-7.
95. Jung YS, Yoon JY, Lee JH, et al. Prognostic factors and long-term clinical outcomes for surgical patients with intestinal Behcet’s disease. Inflamm Bowel Dis. 2011;17:1594-602.
96. Hatemi G, Silman A, Bang D, et al. EULAR Expert Committee. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2008;67:1656-62.
97. Green R, Gu X, Kline-Rogers E, et al. Differences between the pediatric and adult presentation of fibromuscular dysplasia: results from the US registry. Pediatr Nephrol. 2016;31:641-50.
98. Gornik HL, Persu A, Adlam D, et al. First International Consensus on the diagnosis and management of fibromuscular dysplasia. Vasc Med. 2019;24:164-89.
101. Hendricks NJ, Matsumoto AH, Angle JF, et al. Is fibromuscular dysplasia underdiagnosed? Vasc Med. 2014;19:363-7.
102. Nguyen N, Sharma A, West JK, et al. Presentation, clinical features, and results of intervention in upper extremity fibromuscular dysplasia. J Vasc Surg. 2017;66:554-63.
103. Olin JW, Gornik HL, Bacharach JM, et al. Fibromuscular dysplasia: state of the science and critical unanswered questions: a scientific statement from the American heart association. Circulation. 2014;129:1048-78.
104. Stanley JC, Gewertz BL, Bove EL, Sottiurai V, Fry WJ. Arterial fibrodysplasia. Histopathologic character and current etiologic concepts. Arch Surg. 1975;110:561-6.
105. Guill CK, Benavides DC, Rees C, Fenves AZ, Burton EC. Fatal mesenteric fibromuscular dysplasia: a case report and review of the literature. Arch Intern Med. 2004;164:1148-53.
106. Kadian-Dodov D, Goldfinger JZ, Gustavson S, Olin JW. Natural history of cervical artery fibromuscular dysplasia and associated neurovascular events. Cerebrovasc Dis. 2018;46:33-9.
107. Heo S, Kim HJ, Kim B, Lee JH, Kim J, Kim JK. Clinical impact of collateral circulation in patients with median arcuate ligament syndrome. Diagn Interv Radiol. 2018;24:181-6.
108. Cienfuegos JA, Estevez MG, Ruiz-Canela M, et al. Laparoscopic treatment of median arcuate ligament syndrome: analysis of long-term outcomes and predictive factors. J Gastrointest Surg. 2018;22:713-21.
109. Beridze N, Frishman WH. Vascular Ehlers-Danlos syndrome: pathophysiology, diagnosis, and prevention and treatment of its complications. Cardiol Rev. 2012;20:4-7.
110. Pepin M, Schwarze U, Superti-Furga A, Byers PH. Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. N Engl J Med. 2000;342:673-80.
111. Masri H, Loong TH, Meurette G, Podevin J, Zinzindohoue F, Lehur PA. Bowel perforation in type IV vascular Ehlers-Danlos syndrome. A systematic review. Tech Coloproctol. 2018;22:333-41.
112. Driscoll SH, Gomes AS, Machleder HI. Perforation of the superior vena cava: a complication of digital angiography in Ehlers-Danlos syndrome. AJR Am J Roentgenol. 1984;142:1021-2.
